These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31089204)

  • 1. Identification of Glutaminyl Cyclase isoenzyme isoQC as a regulator of SIRPα-CD47 axis.
    Wu Z; Weng L; Zhang T; Tian H; Fang L; Teng H; Zhang W; Gao J; Hao Y; Li Y; Zhou H; Wang P
    Cell Res; 2019 Jun; 29(6):502-505. PubMed ID: 31089204
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions.
    Baumann N; Rösner T; Jansen JHM; Chan C; Marie Eichholz K; Klausz K; Winterberg D; Müller K; Humpe A; Burger R; Peipp M; Schewe DM; Kellner C; Leusen JHW; Valerius T
    Cancer Sci; 2021 Aug; 112(8):3029-3040. PubMed ID: 34058788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy.
    Logtenberg MEW; Jansen JHM; Raaben M; Toebes M; Franke K; Brandsma AM; Matlung HL; Fauster A; Gomez-Eerland R; Bakker NAM; van der Schot S; Marijt KA; Verdoes M; Haanen JBAG; van den Berg JH; Neefjes J; van den Berg TK; Brummelkamp TR; Leusen JHW; Scheeren FA; Schumacher TN
    Nat Med; 2019 Apr; 25(4):612-619. PubMed ID: 30833751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
    Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
    Front Immunol; 2020; 11():18. PubMed ID: 32082311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
    Miller TW; Amason JD; Garcin ED; Lamy L; Dranchak PK; Macarthur R; Braisted J; Rubin JS; Burgess TL; Farrell CL; Roberts DD; Inglese J
    PLoS One; 2019; 14(7):e0218897. PubMed ID: 31276567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology.
    Burgess TL; Amason JD; Rubin JS; Duveau DY; Lamy L; Roberts DD; Farrell CL; Inglese J; Thomas CJ; Miller TW
    PLoS One; 2020; 15(4):e0226661. PubMed ID: 32240171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway.
    Matozaki T; Murata Y; Okazawa H; Ohnishi H
    Trends Cell Biol; 2009 Feb; 19(2):72-80. PubMed ID: 19144521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms in the human inhibitory signal-regulatory protein α do not affect binding to its ligand CD47.
    Hatherley D; Lea SM; Johnson S; Barclay AN
    J Biol Chem; 2014 Apr; 289(14):10024-8. PubMed ID: 24550402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
    Zhang J; Jin S; Guo X; Qian W
    J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of signal-regulatory protein alpha: a link to antigen receptor evolution.
    Hatherley D; Graham SC; Harlos K; Stuart DI; Barclay AN
    J Biol Chem; 2009 Sep; 284(39):26613-9. PubMed ID: 19628875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective.
    Chen YC; Shi W; Shi JJ; Lu JJ
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):1-14. PubMed ID: 34609596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The structure of the macrophage signal regulatory protein alpha (SIRPalpha) inhibitory receptor reveals a binding face reminiscent of that used by T cell receptors.
    Hatherley D; Harlos K; Dunlop DC; Stuart DI; Barclay AN
    J Biol Chem; 2007 May; 282(19):14567-75. PubMed ID: 17369261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel CD47: SIRPα dependent mechanism for the activation of STAT3 in antigen-presenting cell.
    Toledano N; Gur-Wahnon D; Ben-Yehuda A; Rachmilewitz J
    PLoS One; 2013; 8(9):e75595. PubMed ID: 24073274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
    Veillette A; Chen J
    Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.
    Kazama R; Miyoshi H; Takeuchi M; Miyawaki K; Nakashima K; Yoshida N; Kawamoto K; Yanagida E; Yamada K; Umeno T; Suzuki T; Kato K; Takizawa J; Seto M; Akashi K; Ohshima K
    Cancer Sci; 2020 Jul; 111(7):2608-2619. PubMed ID: 32342603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
    Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
    Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological analysis of immunohistochemical expression of CD47 and SIRPα in adult T-cell leukemia/lymphoma.
    Yanagida E; Miyoshi H; Takeuchi M; Yoshida N; Nakashima K; Yamada K; Umeno T; Shimasaki Y; Furuta T; Seto M; Ohshima K
    Hematol Oncol; 2020 Dec; 38(5):680-688. PubMed ID: 32569413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation-induced proteolytic processing of the SIRPα cytoplasmic ITIM in neutrophils propagates a proinflammatory state.
    Zen K; Guo Y; Bian Z; Lv Z; Zhu D; Ohnishi H; Matozaki T; Liu Y
    Nat Commun; 2013; 4():2436. PubMed ID: 24026300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Clustering' SIRPα into the plasma membrane lipid microdomains is required for activated monocytes and macrophages to mediate effective cell surface interactions with CD47.
    Ha B; Lv Z; Bian Z; Zhang X; Mishra A; Liu Y
    PLoS One; 2013; 8(10):e77615. PubMed ID: 24143245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.